DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

Regeneron Pharmaceuticals got a modest confidence bump as Mirae Asset Global ETFs Holdings added 1,712 shares to their ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Humankind Investments increased its stake in Regeneron Pharmaceuticals by 62.3%, showing rising investor interest despite the ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Q1 earnings and revenue miss expectations ... including one paying a 9% dividend—before Wall Street catches on. Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron’s Q1 2025 EPS of $8.22 missed the forecast of $8.48. Revenue for the quarter was $3 billion, below the expected $3.24 billion. The company’s stock dropped 8.19% following the earnings ...